Samsung Biologics plans to set up its first manufacturing facility outside of South Korea in California, North Carolina, Washington and Texas in the United States. The company’s chief executive officer (CEO) John Rim recently informed so. News the Korea Herald.
John Rim said some of the major bio clusters in the United States are located in the four states. The CMO giant has not yet made a final decision and is still reviewing locations.
Speaking to reporters at a press briefing at the BIO International Convention in San Diego, Rim said, “We are currently expanding the scope of the organization. Center No. 4 will start production temporarily from October, which will add 60,000 liters of production capacity. By the end of the second quarter, production will reach 1 lakh 80 thousand liters.”
According to the data, the combined production capacity of the four plants will exceed 620,000 liters, which is 30 percent of the world’s total demand, when production at Samsung Biologics’ megaplant starts after the installation of Incheon’s Songdo. Plant number four will have the largest CMO production capacity in the world, amounting to 256,000 liters.
He said the company was working on acquiring more land in Incheon to set up fifth and sixth production centers. However, no final decision has been taken on the acquisition. The company plans to set up a fifth and sixth manufacturing plant in Songdo.